Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SBBP Strongbridge Biopharma (SBBP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Strongbridge Biopharma Stock (NASDAQ:SBBP) 30 days 90 days 365 days Advanced Chart Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Strongbridge Biopharma alerts:Sign Up Key Stats Today's Range$1.95▼$2.0650-Day Range$1.89▼$2.2952-Week Range$1.85▼$4.26Volume684,684 shsAverage Volume866,464 shsMarket Capitalization$135.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewStrongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.Read More… This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Receive SBBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Strongbridge Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address SBBP Stock News HeadlinesMatinas BioPharma Holdings Inc (MTNB)February 10, 2024 | investing.comLytix Biopharma As Share Price (LYTIX.OL)November 15, 2023 | lse.co.ukAutomatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…November 25, 2024 | Awesomely, LLC (Ad)Ambrx Biopharma Inc AMAMNovember 4, 2023 | morningstar.comHILS Hillstream BioPharma, Inc.August 19, 2023 | seekingalpha.comABUS - Arbutus Biopharma CorporationJuly 1, 2023 | finance.yahoo.comThe Nominees for Best Biopharma CEO of 2015 Are...April 25, 2023 | thestreet.comDay One Biopharma Shares Rise 13% After Positive Topline Results for TovorafenibJanuary 11, 2023 | marketwatch.comSee More Headlines SBBP Stock Analysis - Frequently Asked Questions How were Strongbridge Biopharma's earnings last quarter? Strongbridge Biopharma plc (NASDAQ:SBBP) released its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.09. The biotechnology company earned $10.04 million during the quarter, compared to analyst estimates of $8.83 million. Strongbridge Biopharma had a negative net margin of 115.67% and a negative trailing twelve-month return on equity of 66.82%. What other stocks do shareholders of Strongbridge Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Strongbridge Biopharma investors own include Energy Transfer (ET), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), OPKO Health (OPK) and Viking Therapeutics (VKTX). Company Calendar Last Earnings8/05/2021Today11/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SBBP CUSIPN/A CIK1634432 Webwww.strongbridgebio.com Phone(610) 254-9200FaxN/AEmployees72Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,080,000.00 Net Margins-115.67% Pretax MarginN/A Return on Equity-66.82% Return on Assets-36.21% Debt Debt-to-Equity Ratio0.38 Current Ratio3.00 Quick Ratio2.95 Sales & Book Value Annual Sales$30.73 million Price / Sales4.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book2.04Miscellaneous Outstanding Shares67,829,000Free FloatN/AMarket Cap$135.66 million OptionableOptionable Beta1.58 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:SBBP) was last updated on 11/25/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Strongbridge Biopharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Strongbridge Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
